论文信息 - Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias. - 字舞流文

Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias.

M. Konopleva | M. Andreeff | H. Kantarjian | J. Cortes | G. Borthakur | E. Jabbour | S. Kroll | S. Faderl | M. Richie | G. Lorente | J. Benito | D. Thomas | Damian R. Handisides